Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease: Structural Brain Biomarkers
Restricted accessResearch articleFirst published online May 7, 2019
Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease: Structural Brain Biomarkers
Early Alzheimer’s disease (AD) detection using cerebrospinal fluid (CSF) biomarkers has been recommended as enrichment strategy for trials involving mild cognitive impairment (MCI) patients.
Objective:
To model a prodromal AD trial for identifying MRI structural biomarkers to improve subject selection and to be used as surrogate outcomes of disease progression.
Methods:
APOE ɛ4 specific CSF Aβ42/P-tau cut-offs were used to identify MCI with prodromal AD (Aβ42/P-tau positive) in the WP5-PharmaCog (E-ADNI) cohort. Linear mixed models were performed 1) with baseline structural biomarker, time, and biomarker×time interaction as factors to predict longitudinal changes in ADAS-cog13, 2) with Aβ42/P-tau status, time, and Aβ42/P-tau status×time interaction as factors to explain the longitudinal changes in MRI measures, and 3) to compute sample size estimation for a trial implemented with the selected biomarkers.
Results:
Only baseline lateral ventricle volume was able to identify a subgroup of prodromal AD patients who declined faster (interaction, p = 0.003). Lateral ventricle volume and medial temporal lobe measures were the biomarkers most sensitive to disease progression (interaction, p≤0.042). Enrichment through ventricular volume reduced the sample size that a clinical trial would require from 13 to 76%, depending on structural outcome variable. The biomarker needing the lowest sample size was the hippocampal subfield GC-ML-DG (granule cells of molecular layer of the dentate gyrus) (n = 82 per arm to demonstrate a 20% atrophy reduction).
Conclusion:
MRI structural biomarkers can enrich prodromal AD with fast progressors and significantly decrease group size in clinical trials of disease modifying drugs.
FleisherAS (2010) NerveCenter: Phase III Alzheimer trial halted:Search for therapeutic biomarkers continues. Ann Neurol68, A12–A12.
2.
GreenRC, SchneiderLS, AmatoDA, BeelenAP, WilcockG, SwabbEA, ZavitzKH, Tarenflurbil Phase 3 Study Group (2009) Effect oftarenflurbil on cognitive decline and activities of daily living inpatients with mild Alzheimer disease: A randomized controlled trial. JAMA302, 2557–2564.
3.
VellasB, CarrilloMC, SampaioC, BrashearHR, SiemersE, HampelH, SchneiderLS, WeinerM, DoodyR, KhachaturianZ, CedarbaumJ, GrundmanM, BroichK, GiacobiniE, DuboisB, SperlingR, WilcockGK, FoxN, ScheltensP, TouchonJ, HendrixS, AndrieuS, AisenP (2013) Designing drug trials for Alzheimer’s disease: What we have learnedfrom the release of the phase III antibody trials: A report from the EU/US/ CTAD Task Force. Alzheimers Dement9, 438–444.
4.
RosenWG, MohsRC, DavisKL (1984) A new rating scale forAlzheimer’s disease. Am J Psychiatry141, 1356–1364.
BrooksLG, LoewensteinDA (2010) Assessing the progression of mildcognitive impairment to Alzheimer’s disease: Current trends andfuture directions. Alzheimers Res Ther2, 28.
7.
GrillJD, DiL, LuPH, LeeC, RingmanJ, ApostolovaLG, ChowN, KohannimO, CummingsJL, ThompsonPM, ElashoffD (2013) Estimating sample sizes for predementia Alzheimer’s trials based on the Alzheimer’s Disease Neuroimaging Initiative. Neurobiol Aging34, 62–72.
WolzR, SchwarzAJ, GrayKR, YuP, HillDLG (2016) Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. Neurology87, 1235–1241.
10.
HillDLG, SchwarzAJ, IsaacM, PaniL, VamvakasS, HemmingsR, CarrilloMC, YuP, SunJ, BeckettL, BoccardiM, BrewerJ, BrumfieldM, CantillonM, ColePE, FoxN, FrisoniGB, JackC, KelleherT, LuoF, NovakG, MaguireP, MeibachR, PattersonP, BainL, SampaioC, RaunigD, SoaresH, SuhyJ, WangH, WolzR, StephensonD (2014) Coalition Against Major Diseases/European Medicines Agency biomarkerqualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer’s disease. Alzheimers Dement10, 421–429.
11.
SchuffN, WoernerN, BoretaL, KornfieldT, ShawLM, TrojanowskiJQ, ThompsonPM, JackCR, WeinerMW (2009) MRI of hippocampal volumeloss in early Alzheimers disease in relation to ApoE genotype andbiomarkers. Brain132, 1067–1077.
12.
ClerxL, van RossumIA, BurnsL, KnolDL, ScheltensP, VerheyF, AaltenP, LapuertaP, Van de PolL, Van SchijndelR, De JongR, BarkhofF, WolzR, RueckertD, BocchettaM, TsolakiM, NobiliF, WahlundLO, MinthonL, FrölichL, HampelH, SoininenH, VisserPJ (2013) Measurements of medial temporal lobe atrophy forprediction of Alzheimer’s disease in subjects with mild cognitive impairment. Neurobiol Aging34, 2003–2013.
13.
LeungKK, BartlettJW, BarnesJ, ManningEN, OurselinS, FoxNC (2013) Cerebral atrophy in mild cognitive impairment and Alzheimerdisease: Rates and acceleration. Neurology80, 648–654.
14.
Tabatabaei-JafariH, ShawME, CherbuinN (2015) Cerebral atrophy inmild cognitive impairment: A systematic review with meta-analysis. Alzheimers Dement (Amst)1, 487–504.
15.
Gutiérrez-GalveL, LehmannM, HobbsNZ, ClarksonMJ, RidgwayGR, CrutchS, OurselinS, SchottJM, FoxNC, BarnesJ (2009) Patterns of cortical thickness according to APOE genotype in alzheimer’sdisease. Dement Geriatr Cogn Disord28, 476–485.
16.
DickersonBC, WolkDA (2013) Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampalvolume with spinal fluid amyloid-β and tau. Front Aging Neurosci5, 55.
17.
ElahiS, BachmanAH, LeeSH, SidtisJJ, ArdekaniBA (2015) Corpus callosum atrophy rate in mild cognitive impairment and prodromalAlzheimer’s disease. J Alzheimers Dis45, 921–931.
18.
LeeSH, BachmanAH, YuD, LimJ, ArdekaniBA (2016) Predicting progression from mild cognitive impairment to Alzheimer’s disease using longitudinal callosal atrophy. Alzheimers Dement (Amst)2, 68–74.
19.
BaiF, ZhangZ, WatsonDR, YuH, ShiY, YuanY, QianY, JiaJ (2009) Abnormal integrity of association fiber tracts in amnestic mildcognitive impairment. J Neurol Sci278, 102–106.
20.
GalluzziS, MarizzoniM, BabiloniC, AlbaniD, AntelmiL, BagnoliC, Bartres-FazD, CordoneS, DidicM, FarottiL, FiedlerU, ForloniG, GirtlerN, HenschT, JovicichJ, LeeuwisA, MarraC, MolinuevoJL, NobiliF, ParienteJ, ParnettiL, PayouxP, Del PercioC, RanjevaJP, RolandiE, RossiniPM, SchönknechtP, SoricelliA, TsolakiM, VisserPJ, WiltfangJ, RichardsonJC, BordetR, BlinO, FrisoniGB (2016) Clinical and biomarker profiling of prodromal Alzheimer’sdisease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: A “European ADNI study.”. J Intern Med279, 576–591.
21.
FolsteinMF, FolsteinSE, McHughPR (1975) Mini-Mental State: Apractice method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
22.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current versionand scoring rules. Neurology43, 2412–2414.
BrownLM, SchinkaJA (2005) Development of initial validation of a15-item informant version of the Geriatric Depression Scale. Int J Geriatr Psychiatry20, 911–918.
IglesiasJE, AugustinackJC, NguyenK, PlayerCM, PlayerA, WrightM, RoyN, FroschMP, McKeeAC, WaldLL, FischlB, Van LeemputK (2015) A computational atlas of the hippocampal formation using exvivo, ultra-high resolution MRI: Application to adaptive segmentation of MRI. Neuroimage115, 117–137.
33.
OguzI, FarzinfarM, MatsuiJ, BudinF, LiuZ, GerigG, JohnsonHJ, StynerM (2014) DTIPrep: Quality control of diffusion-weighted images. Front Neuroinform8, 4.
MarizzoniM, FerrariC, GalluzziS, JovicichJ, AlbaniD, BabiloniC, DidicM, ForloniG, MolinuevoJL, NobiliFM, ParnettiL, PayouxP, RossiniPM, SchönknechtP, SoricelliA, TsolakiM, VisserPJ, WiltfangJ, BordetR, CavaliereL, RichardsonJ, BlinO, FrisoniGB (2018) CSF biomarkers and effect of apolipoprotein E genotype, ageand sex on cut-off derivation in mild cognitive impairment. Alzheimers Dement13, P1319.
36.
R Developement Core Team (2015) R: A language and environment forstatistical computing. R Found Stat Comput1, 409.
37.
McLachlanG, PeelD (2000) Finite Mixture Models, John Wiley and Sons, New York.
38.
FraleyC, Raftery, AdrianE (2007) Model-based methods ofclassification: Using the mclust software in chemometrics. J Stat Softw18, 1–13.
39.
DempsterAP, LairdNM, RubinDB (1977) Maximum likelihood fromincomplete data via the EM algorithm. J R Stat Soc Ser BMethodol39, 1–38.
40.
BurnhamKP, AndersonDR, HuyvaertKP (2011) AIC model selection andmultimodel inference in behavioral ecology: Some background, observations, and comparisons. Behav Ecol Sociobiol65, 23–35.
41.
LiuG, LiangK-Y (1997) Sample size calculations for studies with correlated observations. Biometrics53, 937.
42.
HollandD, McEvoyLK, DaleAM (2012) Unbiased comparison of samplesize estimates from longitudinal structural measures in ADNI. Hum Brain Mapp33, 2586–2602.
43.
NestorSM, RupsinghR, BorrieM, SmithM, AccomazziV, WellsJL, FogartyJ, BarthaR (2008) Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database. Brain131, 2443–2454.
44.
FujishimaM, KawaguchiA, MaikusaN, KuwanoR, IwatsuboT, MatsudaH (2017) Sample size estimation for Alzheimer’s disease trials fromJapanese ADNI serial magnetic resonance imaging. J Alzheimers Dis56, 75–88.
45.
HollandD, BrewerJB, HaglerDJ, Fennema-NotestineC, DaleAM (2009) Subregional neuroanatomical change as a biomarker for Alzheimer’sdisease. Proc Natl Acad Sci U S A106, 20954–20959.
FoxNC, CousensS, ScahillR, HarveyRJ, RossorMN (2000) Usingserial registered brain magnetic resonance imaging to measuredisease progression in Alzheimer disease - Power calculations andestimates of sample size to detect treatment effects. Arch Neurol57, 339–344.
48.
JackCR, ShiungMM, GunterJL, O’BrienPC, WeigandSD, KnopmanDS, BoeveBF, IvnikRJ, SmithGE, ChaRH, TangalosEG, PetersenRC, PetersenRC (2004) Comparison of different MRI brain atrophy ratemeasures with clinical disease progression in AD. Neurology62, 591–600.
49.
SchottJM, PriceSL, FrostC, WhitwellJL, RossorMN, FoxNC (2005) Measuring atrophy in Alzheimer disease: A serial MRI study over 6and 12 months. Neurology65, 119–124.
50.
FerrariniL, PalmWM, OlofsenH, van BuchemMA, ReiberJHC, Admiraal-BehloulF (2006) Shape differences of the brain ventriclesin Alzheimer’s disease. Neuroimage32, 1060–1069.
51.
GieselFL, HahnHK, ThomannPA, WidjajaE, WignallE, Von Tengg-KobligkH, PantelJ, GriffithsPD, PeitgenHO, SchroderJ, EssigM (2006) Temporal horn index and volume of medial temporallobe atrophy using a new semiautomated method for rapid and precise assessment. Am J Neuroradiol27, 1454–1458.
FoxNC, BlackRS, GilmanS, RossorMN, GriffithSG, JenkinsL, KollerM (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology64, 1563–1572.
54.
OttBR, CohenR a, GongvatanaA, OkonkwoOC, JohansonCE, StopaEG, DonahueJE, SilverbergGD, Alzheimer’s Disease Neuroimaging Initiative (2010) Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer’s disease. J Alzheimers Dis20, 647–657.
55.
SilverbergGD, MayoM, SaulT, RubensteinE, McGuireD (2003) Alzheimer’s disease, normal-pressure hydrocephalus, and senescentchanges in CSF circulatory physiology: A hypothesis. Lancet Neurol2, 506–511.
56.
RubensteinE (1998) Relationship of senescence of cerebrospinal fluid circulatory system to dementias of the aged. Lancet351, 283–285.
57.
TsivilisD, VannSD, DenbyC, RobertsN, MayesAR, MontaldiD, AggletonJP (2008) A disproportionate role for the fornix andmammillary bodies in recall versus recognition memory. Nat Neurosci11, 834–842.
58.
DidicM, BarbeauEJ, FelicianO, TramoniE, GuedjE, PoncetM, CeccaldiM (2011) Which memory system is impaired first in alzheimer’s disease?J Alzheimers Dis27, 11–22.
